Forest Hopeful No More Trials Needed For Milnacipran Fibromyalgia Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
Priority review could bring the drug to market in June, at the same time competitor Lilly’s Cymbalta may be approved for the indication.